drugset / Trial / NCT07364305
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
NaSingle-groupOpen-labelTreatment
Summary
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. A prospective study was conducted on the data of locally advanced unresectable ICC patients receiving GC-HAIC combined with immunosuppressive therapy, evaluating the treatment efficacy and safety.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
Indications
No indication recorded.